Description

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk as part of their next-generation obesity pipeline. Amylin is a pancreatic hormone co-secreted with insulin that plays a critical role in regulating postprandial glucose and satiety. Cagrilintide was engineered with fatty acid modifications to extend its half-life to approximately 7 days, enabling once-weekly dosing. In Phase III trials as part of the CagriSema combination (with semaglutide), it has demonstrated up to 22.7% body weight reduction — substantially exceeding the efficacy of semaglutide alone. This makes it one of the most promising agents in the obesity pharmacotherapy pipeline. Beyond weight loss, it improves glycemic control, reduces postprandial glucose excursions, and has favorable effects on lipid profiles.

Key Characteristics

Investigated Benefits

* Benefits based on preclinical/animal research unless otherwise noted.